TG Therapeutics traded at $40.79 this Thursday May 14th, decreasing $1.86 or 4.36 percent since the previous trading session. Looking back, over the last four weeks, TG Therapeutics lost 17.89 percent. Over the last 12 months, its price rose by 21.44 percent. Looking ahead, we forecast TG Therapeutics to be priced at 41.97 by the end of this quarter and at 39.42 in one year, according to Trading Economics global macro models projections and analysts expectations.
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that is focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The Company’s two programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase I clinical development. The Company’s clinical programs are focused on Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), CLL, and MS. MZL comprises a group of indolent (slow-growing) mature B-cell non-Hodgkin lymphomas (NHLs). MZL consists of three different subtypes extranodal MZL of the mucosal-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZL), and splenic marginal zone lymphoma (SMZL).